ECSP045029A - Composiciones de valdecoxib de disgregación intraoral - Google Patents

Composiciones de valdecoxib de disgregación intraoral

Info

Publication number
ECSP045029A
ECSP045029A EC2004005029A ECSP045029A ECSP045029A EC SP045029 A ECSP045029 A EC SP045029A EC 2004005029 A EC2004005029 A EC 2004005029A EC SP045029 A ECSP045029 A EC SP045029A EC SP045029 A ECSP045029 A EC SP045029A
Authority
EC
Ecuador
Prior art keywords
compositions
intraoral
disgregation
valdecoxib
valdecoxib compositions
Prior art date
Application number
EC2004005029A
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of ECSP045029A publication Critical patent/ECSP045029A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas de disgregación intraoral que contienen valdecoxib como ingrediente activo, a procesos para preparar dichas composiciones, y a métodos de tratamiento de trastornos mediados por la ciclooxigenasa-2 que comprenden administrar por vía oral dichas composiciones a un sujeto.
EC2004005029A 2001-09-26 2004-03-23 Composiciones de valdecoxib de disgregación intraoral ECSP045029A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32535601P 2001-09-26 2001-09-26

Publications (1)

Publication Number Publication Date
ECSP045029A true ECSP045029A (es) 2004-04-28

Family

ID=23267542

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005029A ECSP045029A (es) 2001-09-26 2004-03-23 Composiciones de valdecoxib de disgregación intraoral

Country Status (25)

Country Link
US (1) US20030181501A1 (es)
EP (2) EP1490035A1 (es)
JP (2) JP2005506987A (es)
KR (2) KR20040058189A (es)
CN (2) CN1633281A (es)
AP (2) AP2004002998A0 (es)
AR (1) AR037239A1 (es)
BR (2) BR0212861A (es)
CA (2) CA2461044A1 (es)
CO (2) CO5570659A2 (es)
EA (2) EA200400357A1 (es)
EC (1) ECSP045029A (es)
GE (1) GEP20063856B (es)
HK (1) HK1079988A1 (es)
IL (2) IL160848A0 (es)
IS (2) IS7177A (es)
MA (2) MA27542A1 (es)
MX (2) MXPA04002652A (es)
NO (2) NO20041258L (es)
OA (2) OA13060A (es)
PL (2) PL369298A1 (es)
TN (2) TNSN04045A1 (es)
WO (2) WO2003026623A1 (es)
YU (1) YU34804A (es)
ZA (2) ZA200401953B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005002557A1 (en) * 2003-07-03 2005-01-13 Warner-Lambert Company Llc Pharmaceutical compositions including an ether and selective cox-2 inhibitor and uses thereof
US20050186271A1 (en) * 2004-02-24 2005-08-25 Sheskey Paul J. Process for dispersing a fluid in a mass of solid particles
JP5551852B2 (ja) * 2004-08-10 2014-07-16 味の素株式会社 苦味の低減したナテグリニド含有製剤
JP5209876B2 (ja) * 2004-12-28 2013-06-12 エーザイ・アール・アンド・ディー・マネジメント株式会社 速崩壊性錠剤及びその製造方法
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
CN101340899A (zh) * 2005-12-20 2009-01-07 卫材R&D管理有限公司 含有脂溶性药物的口腔内速崩片
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8202535B2 (en) 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
WO2007087188A2 (en) * 2006-01-20 2007-08-02 Merck & Co., Inc. Taste-masked tablets and granules
US20070196494A1 (en) * 2006-02-17 2007-08-23 Arnaud Grenier Low-friability, patient-friendly orally disintegrating formulations
JP2009537554A (ja) * 2006-05-19 2009-10-29 ソマクソン ファーマシューティカルズ インコーポレイテッド 不眠症を治療するための、口腔内、舌下および急速融解製剤を含む、低用量ドキセピン製剤、ならびにその使用
KR101903781B1 (ko) * 2007-06-06 2018-11-13 바스프 에스이 급속 붕해 정제의 제조를 위한 제약 제제
JP2010529071A (ja) * 2007-06-06 2010-08-26 ビーエーエスエフ ソシエタス・ヨーロピア 速崩性錠剤製造のための医薬製剤
KR20100033400A (ko) * 2007-06-06 2010-03-29 바스프 에스이 급속 붕해 정제의 제조를 위한 제약 제제
WO2008148734A1 (de) * 2007-06-06 2008-12-11 Basf Se Pharmazeutische formulierung für die herstellung von kau- und lutsch-tabletten
CA2704929C (en) * 2007-08-07 2018-05-15 Pamela Palmer Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms
WO2009118589A2 (en) 2008-03-24 2009-10-01 Wockhardt Research Centre Orally disintegrating compositions of rhein or diacerein
US8945592B2 (en) * 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
CN102988318A (zh) * 2008-11-25 2013-03-27 田边三菱制药株式会社 口腔速崩片及其制备方法
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US20110091544A1 (en) * 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
FR2968995B1 (fr) * 2010-12-16 2013-03-22 Sanofi Aventis Composition pharmaceutioue pour une administration par voie orale destinee a eviter le mesusage
CN106822007B (zh) 2015-09-11 2021-12-31 西姆莱斯股份公司 口服制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5576014A (en) * 1994-01-31 1996-11-19 Yamanouchi Pharmaceutical Co., Ltd Intrabuccally dissolving compressed moldings and production process thereof
US5633272A (en) * 1995-02-13 1997-05-27 Talley; John J. Substituted isoxazoles for the treatment of inflammation
SK74396A3 (en) * 1995-06-13 1997-04-09 American Home Prod Organoleptically acceptable oral pharmaceutical compositions
DK0855988T3 (da) * 1995-10-20 2002-08-19 Upjohn Co Blisterpakning
SK284330B6 (sk) * 1996-05-17 2005-01-03 Merck & Co., Inc. Použitie 3-fenyl-4-(4-metylsulfonyl)fenyl)-2-(5H)-furanónu
EP0863134A1 (en) * 1997-03-07 1998-09-09 Merck Frosst Canada Inc. 2-(3,5-difluorophenyl)-3-(4-(methyl-sulfonyl)phenyl)-2-cyclopenten-1-one useful as an inhibitor of cyclooxygenase-2
US6465009B1 (en) * 1998-03-18 2002-10-15 Yamanouchi Pharmaceutical Co., Ltd. Water soluble polymer-based rapidly dissolving tablets and production processes thereof
CA2362816C (en) * 1999-12-08 2007-02-06 Pharmacia Corporation Valdecoxib compositions
US6316029B1 (en) * 2000-05-18 2001-11-13 Flak Pharma International, Ltd. Rapidly disintegrating solid oral dosage form
US6800297B2 (en) * 2000-06-15 2004-10-05 Acusphere, Inc. Porous COX-2 inhibitor matrices and methods of manufacture thereof
CN1638739A (zh) * 2000-08-18 2005-07-13 法玛西雅厄普约翰美国公司 治疗成瘾性障碍的化合物
EP1309315B1 (en) * 2000-08-18 2006-06-14 Pharmacia Corporation Rapidly disintegrating oral formulation of valdecoxib

Also Published As

Publication number Publication date
US20030181501A1 (en) 2003-09-25
WO2003026697A3 (en) 2003-07-03
CN1633281A (zh) 2005-06-29
WO2003026623A1 (en) 2003-04-03
TNSN04047A1 (fr) 2006-06-01
CO5570659A2 (es) 2005-10-31
EA200400357A1 (ru) 2004-08-26
CA2461630A1 (en) 2003-04-03
NO20041532L (no) 2004-04-15
BR0212778A (pt) 2004-12-07
EP1429736A2 (en) 2004-06-23
CA2461044A1 (en) 2003-04-03
HK1079988A1 (zh) 2006-04-21
EA200400352A1 (ru) 2004-12-30
WO2003026623A8 (en) 2004-09-30
IL160855A0 (en) 2004-08-31
IS7177A (is) 2004-03-11
PL369297A1 (en) 2005-04-18
MXPA04002798A (es) 2004-07-05
MA27542A1 (fr) 2005-10-03
NO20041258L (no) 2003-03-27
AP2004002999A0 (en) 2004-03-31
BR0212861A (pt) 2004-10-05
GEP20063856B (en) 2006-06-26
TNSN04045A1 (fr) 2006-06-01
MXPA04002652A (es) 2004-06-07
OA13060A (en) 2006-11-10
JP2005506987A (ja) 2005-03-10
IS7178A (is) 2004-03-11
WO2003026697A2 (en) 2003-04-03
EP1490035A1 (en) 2004-12-29
AR037239A1 (es) 2004-11-03
YU34804A (sh) 2006-08-17
IL160848A0 (en) 2004-08-31
AP2004002998A0 (en) 2004-03-31
PL369298A1 (en) 2005-04-18
ZA200401953B (en) 2005-05-09
CN1703203A (zh) 2005-11-30
KR20040044990A (ko) 2004-05-31
CO5570684A2 (es) 2005-10-31
KR20040058189A (ko) 2004-07-03
MA27682A1 (fr) 2006-01-02
OA12707A (en) 2006-06-26
JP2005512964A (ja) 2005-05-12
ZA200402364B (en) 2005-01-13

Similar Documents

Publication Publication Date Title
NO20076508L (no) Acyloksykarbamat prodroger av traneksaminsyre og fremgangsmater for fremstilling og anvendelse derav
EP1558220A4 (en) ORAL COMPOSITIONS FOR THE TREATMENT OF DISEASES
UY35624A (es) Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
SG157406A1 (en) Oral medicament for the modified release of at least one active principle, in multi-microcapsule form
NZ591873A (en) Co-crystals of tramadol and nsaids
EP4327888A3 (en) Oral formulations of cytidine analogs and methods of use thereof
MX2009002196A (es) Oblea de buprenorfina para terapia de sustitucion de farmacos.
MX2009011444A (es) Titulacion del tapentadol.
SE0300831D0 (sv) New formulations and use therof
TR200900878A2 (tr) Tek bir dozaj formunda kombine edilen farmasötik formülasyonlar
WO2008116890A3 (en) Pharmaceutical compositions comprising flibanserin and a further agent in the treatment of sexual disorders
CO6270217A2 (es) Formulaciones galenicas de alisquireno y valsartan
FR2878161B1 (fr) Forme medicamenteuse orale, solide et concue pour eviter le mesusage
PT1383752E (pt) 3-piperidinopropiofenonas deuteradas assim como farmacos contendo estes compostos
EA200702522A1 (ru) Система доставки лекарств в полость рта и способы ее применения
TR200900879A2 (tr) Aktif maddelerin tek bir dozaj formunda kombine edildiği farmasötik bileşimler
EA201170108A1 (ru) Сосательная композиция для лечения воспалительных заболеваний полости рта и глотки
UA90893C2 (ru) Пероральная дозированная форма производных гемцитабина
WO2007144080A3 (de) Antidepressiva-kombinations-wafer
MXPA05008843A (es) Sistema terapeutico que comprende amoxicilina y acido clavulanico.
ECSP045056A (es) Composiciones de valdecoxib de disgregación intraoral preparadas mediante un procedimiento de desecación por pulverizacion
BRPI0516545A (pt) uso de óleo de lavanda para a profilaxia e tratamento de neurastenia, distúrbios de somatização e outras doenças associadas ao estresse
CR7289A (es) Composiciones de valdecoxib de disgregacion intraoral
TR200900880A2 (tr) Tek bir dozaj formunda kombine edilen farmasötik bileşimler.